RxDoctor Payments Data

Afzaal Iqbal

Pain Medicine · Fountain Valley, CANPI 1861782674

Payments from drug & device makers

$11,346in general payments, 2019–2025

Across 341 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Vertiflex, Inc.$2K
  • AbbVie$1K
  • Collegium Pharmaceutical, Inc.$305
  • Nevro Corp.$254
  • plus $2K from 39 others

What the payments were for

  • Travel & lodging$3,62332%
  • Food & beverage$7,70168%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,346 in reported general payments places this provider in the 80th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$181,382
Medicare patients
162
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl105$175,160
Nurtec OdtRimegepant Sulfate13$18,793
NucyntaTapentadol Hcl15$18,690
UbrelvyUbrogepant13$13,363
BelbucaBuprenorphine Hcl17$12,950
OxycontinOxycodone Hcl15$12,520
MounjaroTirzepatide13$11,872
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl59$11,073
Buprenorphine18$7,375
MovantikNaloxegol Oxalate14$5,366
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen79$2,903
Asa-Butalb-Caffeine-CodeineCodeine/Butalbital/Asa/Caffein20$2,575
Pregabalin91$2,483
Oxycodone Hcl59$1,233
Tramadol Hcl ErTramadol Hcl19$1,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$28$175,160105 claims
Collegium Pharmaceutical, Inc.Nucynta, Belbuca$305$31,64032 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl$21$19,19688 claims
PfizerNurtec Odt$50$18,79313 claims
AbbVieUbrelvy$1,363$13,36313 claims
Lilly USA, LLCMounjaro$101$11,87213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 pain medicine providers in California.

Other pain medicine in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →